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AbstrAct
Leber congenital amaurosis (LCA) and early-onset 
severe retinal dystrophy (EOSRD) are both genetically 
and phenotypically heterogeneous, and characterised 
clinically by severe congenital/early infancy visual loss, 
nystagmus, amaurotic pupils and markedly reduced/
absent full-field electroretinograms. The vast genetic 
heterogeneity of inherited retinal disease has been 
established over the last 10 - 20 years, with disease-
causing variants identified in 25 genes to date associated 
with LCA/EOSRD, accounting for 70–80% of cases, 
with thereby more genes yet to be identified. There is 
now far greater understanding of the structural and 
functional associations seen in the various LCA/EOSRD 
genotypes. Subsequent development/characterisation 
of LCA/EOSRD animal models has shed light on the 
underlying pathogenesis and allowed the demonstration 
of successful rescue with gene replacement therapy 
and pharmacological intervention in multiple models. 
These advancements have culminated in more than 
12 completed, ongoing and anticipated phase I/II and 
phase III gene therapy and pharmacological human 
clinical trials. This review describes the clinical and 
genetic characteristics of LCA/EOSRD and the differential 
diagnoses to be considered. We discuss in further detail 
the diagnostic clinical features, pathophysiology, animal 
models and human treatment studies and trials, in the 
more common genetic subtypes and/or those closest to 
intervention.
IntroductIon
Inherited retinal disease (IRD) represents the second 
most common cause of legal blindness in childhood 
and the leading cause among the working aged 
population in England and Wales.1 Prior to iden-
tification of the causative genes, clinicians clas-
sified patients into groups based on Mendelian 
inheritance, age of onset and clinical features. The 
discovery of the underlying genetic causes over the 
last two decades has led to far greater understanding 
of disease mechanisms in IRD which has informed 
development of novel therapies, culminating in the 
first gene therapy trials for RPE65-associated Leber 
congenital amaurosis (LCA)/Early Onset Severe 
Retinal Dystrophy (EOSRD) in 2008.2–4
LCA was first described by Theodore Leber 
in 1869 and is now used to describe a group of 
severe recessively inherited, early infantile onset 
rod–cone dystrophies.5 In 1916, Leber described 
what he considered a milder form of the same 
disease6 which has had several names, including 
EOSRD, severe early childhood-onset retinal 
dystrophy (SECORD)7 and early-onset retinitis 
pigmentosa. Whereas LCA is congenital or pres-
ents within the first few months of life, is asso-
ciated with nystagmus, poor pupil responses 
and in most instances an undetectable full-field 
electroretinogram (ERG); EOSRD/SECORD is 
defined as a severe retinal dystrophy presenting 
after infancy and usually before the age of 5 
years. Other distinguishing features of EOSRD/
SECORD include better residual visual func-
tion and small ERG signals, particularly for the 
lesser-affected photoreceptor system. Of note, 
there is significant overlap between the molec-
ular causes of LCA and EOSRD, with some genes 
causing both clinical phenotypes. However, 
certain genes are more frequently associated with 
LCA, for example, GUCY2D, NMNAT1, CEP290 
and AIPL1, whereas mutations in others including 
RPE65, LRAT and RDH12, more commonly result 
in an EOSRD phenotype.
To date, mutations in 25 genes have been iden-
tified as causing LCA/EOSRD; most are expressed 
solely or predominantly in the retina or the retinal 
pigment epithelium (RPE).8 These genes have been 
shown to encode proteins with a diverse range of 
retinal functions, including phototransduction, the 
visual cycle and photoreceptor development/integ-
rity (table 1, figure 1).9–11
Given recent advances in understanding of the 
molecular basis of these disorders and the ongoing 
clinical trials of novel therapies, we herein review 
the clinical characteristics, animal models and 
pathophysiology of LCA/EOSRD, prioritising the 
more common genotypes and/or those closest to 
intervention.
clinical characteristics
LCA/EOSRD has a prevalence between 1 in 
33 00012 to 1 in 81 000,13 and is believed to account 
for ≥5% of all IRD.12
LCA is associated with severe visual impairment 
from birth or the first few months of life accompa-
nied by roving eye movements or nystagmus and 
poor pupillary light responses. Eye poking, the 
‘oculodigital’ sign, is common. The ERG is unde-
tectable or severely abnormal. Fundus examina-
tion may be normal at presentation, but a variety 
of abnormal fundus appearances may be present 
or develop over time, including disc pallor, vessel 
attenuation or mild peripheral pigmentary reti-
nopathy. There may also be disc drusen, optic disc 
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oedema or pseudopapilloedema, a flecked retina, maculop-
athy or nummular pigmentation (figure 2). Affected infants 
often have high hyperopia, or less commonly high myopia, 
suggesting impaired emmetropisation.14
The rate of loss of visual function and early childhood 
visual acuity vary markedly in patients with LCA/EOSRD, 
with certain genotypes (eg, GUCY2D and AIPL1-LCA) known 
to be more severe than others, with earlier more profound 
visual loss. Although visual outcome is variable, vision when 
the child is old enough to be reliably tested is in the region of 
3/60 to perception of light. Given the often severe and early 
visual loss, other areas of development including speech, social 
skills and behaviour may be delayed; early involvement of a 
specialist paediatrician with expertise in the developmental 
needs of children with visual impairment can significantly 
mitigate/delay disruption to these other fundamental areas of 
childhood development.15
The  identified  genes  account  for  approximately  70%–80% 
of LCA/EOSRD cases (table 1, figure 1 and below), with 
GUCY2D, CEP290, CRB1, RDH12 and RPE65 being the most 
common.9 16–19 It has been possible to identify certain charac-
teristic associated phenotypes (figure 2 and below): RDH12-as-
sociated disease, which gives rise to an EOSRD phenotype is 
characterised by early-dense intraretinal pigment migration 
pigmentation and maculopathy. CRB1-associated disease has 
nummular pigmentation, maculopathy, relative preservation of 
para-arteriolar RPE, with retinal thickening and loss of lami-
nation on optical coherence tomography. TULP1, AIPL1 and 
NMNAT1-associated disease are also characterised by maculop-
athy which in the case of patients with NMNAT1 mutations is of 
early onset and extensive.
Most cases of LCA/EOSRD occur in otherwise normal infants 
and any non-ocular symptoms or signs should be investigated 
for syndromic retinal dystrophies or neurometabolic disease, 
usually in conjunction with a paediatrician. Renal involvement 
(nephronophthisis which can lead to end-stage renal failure) 
may be seen in some genetic subtypes of LCA/EOSRD (eg, 
IQCB1, IFT140 and CEP290) as part of syndromes including 
Senior-Loken Syndrome and Joubert Syndrome.20–22 Early 
molecular diagnosis can help prioritise which children should 
have ongoing systemic investigations.
The differential diagnosis of an infant with severe visual 
loss and nystagmus is broad and includes both syndromic and 
non-syndromic diseases (table 2). Conditions that are important 
to be distinguished from LCA/EOSRD include complete and 
incomplete Achromatopsia, S-cone monochromatism, complete 
and incomplete congenital stationary night blindness and albi-
nism; however careful examination and detailed investigation 
including electrophysiology usually allow an accurate diagnosis 
to be established. Molecular genetic testing may then allow a 
more specific diagnosis (table 2).
table 1 Overview of the genes associated with LCA/EOSRD, the encoded proteins, their proposed function(s) and estimated frequency
Locus name
causative
gene Protein Protein function(s)
Approximate 
frequency
LCA 1 GUCY2D∗ Guanylate cyclase-1 Phototransduction 10%–20%
LCA 2 RPE65† Retinoid isomerase Retinoid cycle 5%–10%
LCA 3 SPATA7 Spermatogenesis-associated protein 7 Photoreceptor ciliary transport 3%
LCA 4 AIPL1∗ Aryl-hydrocarbon-interacting-protein-like 1 Phototransduction/protein biosynthesis <5%
LCA 5 LCA5 Libercilin Photoreceptor ciliary transport 1%–2%
LCA 6 RPGRIP1
Retinitis pigmentosa GTPase regulator-interacting 
protein 1 Photoreceptor ciliary transport 5%
LCA 7 CRX Cone–rod homeobox Photoreceptor morphogenesis 1%
LCA 8 CRB1∗ Crumbs homologue 1 Photoreceptor morphogenesis 10%
LCA 9 NMNAT1∗ Nicotinamide nucleotide adenyltransferase1 Coenzyme NAD biosynthesis Unknown
LCA 10 CEP290 Centrosomal protein 290 kDA Photoreceptor ciliary transport 15%–20%
LCA 11 IMPDH1 Inosine 5’—monophosphate dehydrogenase 1 Guanine synthesis 5%
LCA 12 RD3 Protein RD3 Protein trafficking <1%
LCA 13 RDH12† Retinol dehydrogenase 12 Retinoid cycle 10%
LCA 14 LRAT† Lecithin:retinol acyl transferase Retinoid cycle <1%
LCA 15 TULP1 Tubby-like protein Photoreceptor ciliary transport <1%
LCA 16 KCNJ13 Kir7 inwardly rectifying potassium channel Phototransduction Unknown
LCA 17 GDF6 Growth differentiation factor 6 Photoreceptor morphogenesis Unknown
OTX2 Orthodenticle homeobox 2 protein Photoreceptor differentiation Unknown
CABP4 Calcium-binding protein 4 Phototransduction Unknown
CLUAP1 Clusterin associated protein 1 Photoreceptor ciliary transport Unknown
IQCB1 IQ motif containing B1 protein Photoreceptor ciliary transport Unknown
DTHD1 Death-domain containing protein 1 Unknown Unknown
IFT140
Intraflagellar transport 140 chlamydomonas 
homologue protein Photoreceptor ciliary transport
Unknown
ALMS1 ALMS Protein Photoreceptor ciliary transport Unknown
PRPH2 Perpherin Photoreceptor outer segment structure/stabilisation Unknown
*Genes associated with EOSRD.
†Genes more frequently associated with LCA.
Other genes have shown no clear predilection.
EOSRD, early-onset severe retinal dystrophy; LCA, Leber congenital amaurosis.
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selected specific genotypes
GUCY2D-associated LCA
GUCY2D was the first gene to be associated with LCA/EOSRD 
and is one of the most common, accounting for approximately 
10%–20%  of  cases.16GUCY2D is known to encode retinal 
guanylate cyclase-1 (RetGC1), expressed in photoreceptor outer 
segments, to a greater degree in cones than rods.23 24 RetGC1 
is known to play an important role in photoreceptor recovery 
following phototransduction, thereby disease-causing variants 
in GUCY2D and subsequent RetGC1 deficiency result in the 
biochemical equivalent of chronic light exposure.16
Patients with GUCY2D-associated LCA often have relatively 
normal fundi, and also experience significant photophobia in 
contrast to most other LCA/EOSRD genotypes. There can be 
relatively preserved outer retinal / photoreceptor structure 
on optical coherence tomography (OCT) in many patients, 
although foveal cone outer segment abnormalities and foveal 
cone loss has been observed.25 26 In contrast to other forms of 
LCA/EOSRD which have a rod–cone dystrophy phenotype, 
in GUCY2D disease patients often retain substantial rod func-
tion, with a smaller subset having detectable but reduced cone 
function (ie, cone–rod disease), based on ERG, psychophysical 
assessments and vision-guided mobility testing.25 Due to the 
majority of patients lacking cone-mediated vision, patients often 
present with markedly reduced visual acuity and a lack of colour 
perception.27
Disease mechanisms and interventional approaches have been 
explored in several animal models of GUCY2D-LCA. Initially, 
gene replacement was investigated using an HIV1-based lenti-
viral vector in a naturally occurring chicken model and showed 
improved optokinetic reflexes and volitional visual behaviour.28 
Subsequently, multiple groups have had therapeutic success in 
Figure 1 Spatial representation of expression of LCA/EOSRD genes, grouped according to their proposed function. EOSRD, early-onset severe retinal 
dystrophy; LCA, Leber congenital amaurosis.
Figure 2 Colour fundus photographs of patients with recognisable LCA/EOSRD clinical phenotypes. (A) RPE65-retinopathy, associated with a 
blonde fundus, peripheral, white punctate lesions and normal central macular appearance in keeping with central preservation of outer retina. (B) 
CRB1-retinopathy characterised by nummular pigmentation, periarteriolar sparing of the RPE and macular atrophy. (C) RDH12-retinopathy with 
characteristic dense intraretinal pigmentation and macular atrophy with pigmentation and yellowing. EOSRD, early-onset severe retinal dystrophy; 
LCA, Leber congenital amaurosis; RPE, retinal pigment epithelium.
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engineered mouse models. Both adeno-associated virus serotype 
5 (AAV5) and recombinant adeno-associated virus serotype 2/8 
(AAV 2/8) vectors carrying animal and human complementary 
DNA (cDNA), respectively, have been shown to rescue retinal 
function and preserve cone photoreceptors in RetGC1 knock-out 
mouse models.29–31 Moreover, an AAV8 based-gene replacement 
therapy, using the tyrosine capsid mutant AAV8(Y733F), has been 
shown to restore both useful cone and rod-mediated vision in a 
RetGC1/RetGC2 double knock-out mouse.32 These successful 
animal studies combined with the relative outer retinal preser-
vation observed in patients with GUCY2D-LCA has resulted in 
advanced preparation for a human gene therapy trial.
RPE65-associated LCA
RPE65-associated LCA/EOSRD accounts for approximately 
5%–10%  of  cases  and  has  been  the  subject  of  the most  clin-
ical trials to date.9RPE65 encodes a 65kD retinoid isomerase 
expressed in the RPE; a critical component of the retinoid 
(visual) cycle.33 34 As such, patients with RPE65 deficiency have 
a lack of 11-cis-retinal. Most children with RPE65 deficiency 
have an EOSRD phenotype with profound night blindness from 
birth but residual cone-mediated vision and often mild if any 
nystagmus. It has been suggested that cone photoreceptors have 
an alternative supply of 11-cis-retinal independent of RPE65, 
thus allowing cone-mediated vision in younger patients.35 
However, due to the 11-cis-retinal deficiency in rod photorecep-
tors there is early and profound nyctalopia.
OCT studies have demonstrated relatively normal retinal 
thickness in some patients; with more commonly a central 
macular area of relatively preserved retina with a ring of thin-
ning or more widespread retinal loss. There appears to be no 
clear relationship between age and thinning in the first three 
decades.36 37 This phenotypic variability irrespective of age, 
and varying both between and within families, is typical of the 
marked heterogeneity characterising IRD as a whole. RPE65-de-
ficiency is also associated with reduced or absent autofluores-
cence on fundus autofluorescence imaging, suggesting low or 
absent levels of lipofuscin in the RPE.38
In 2001, Acland et al described successful gene therapy in 
Briard dogs with RPE65-retinopathy using subretinal delivery 
of recombinant adeno-associated virus serotype 2 (AAV2) vector 
with canine RPE65 cDNA under the control of the cytomeg-
alovirus chicken beta actin promoter.39 Injected eyes of these 
dogs showed improved ERG, pupillometry and flash evoked 
cortical potentials in the dark-adapted state. Furthermore, these 
improvements were sustained for over 10 years.39 40 Subse-
quently, murine models of RPE65 deficiency have been charac-
terised and rescued using gene replacement therapy, with signif-
icant improvement in visual function in both RPE65-/- mice and 
naturally occurring RPE65 mutant mice (Rd12 mouse) and the 
demonstration of a dose–response relationship.36 41–44
Success in canine and murine models39 45 resulted in four 
phase 1 gene therapy clinical trials in humans in close succes-
sion.2–4 46 The 2 to 5-year follow-up data on all four trials has 
been very encouraging, showing the intervention to be safe with 
varying levels of efficacy noted; however, most studies at later 
intervals have shown a lack of durability of the improvements, 
with continuing retinal degeneration even in patients with 
improved retinal function.46–49 Of the 12 patients enrolled in 
the UK trial, an initial improvement in retinal sensitivity, dark-
adapted perimetry and vision-guided mobility was noted in six, 
five and three patients, respectively. This improvement was not 
sustained, with only two patients having residual improvement 
greater than preinterventional levels, 3  years following subret-
inal injection.47 Similar results were noted in the other three 
clinical trials, with Testa et al reporting sustained improvement 
in visual acuity, visual field, nystagmus frequency and pupillom-
etry at 3 years.48 Weleber et al noted variable improvement in 
one or more parameters of visual function in 9 of 12 patients.46 
Jacobson et al described visual function improved in all 15 
patients, to different degrees, with improvements being local-
ised to treated areas, but a waning of improvement over time 
and continued retinal degeneration.49 It has been proposed that 
continued retinal degeneration may be due to suboptimal RPE65 
expression in the human retina, resulting in subsequent work to 
optimise the vector, promoter and transgene hoping to result in 
more durable benefit.47 50
Acknowledging the known impaired structural properties of 
the visual pathway observed in visually deprived animals51 and 
blind human studies,52 Ashtari et al investigated the plasticity of 
the visual system following retinal gene therapy in patients with 
RPE65-LCA using non-invasive multimodal neuroimaging.53 
table 2 Selected conditions/syndromes to be considered in the differential diagnosis of isolated LCA/EOSRD
condition/syndrome Assessments and features that assist in distinguishing from LcA/Eosrd
Achromatopsia Achromatopsia is characterised by absent/markedly reduced cone responses with normal rod ERG responses and a stationary natural 
history; compared with the flat/markedly reduced full-field ERGs and progressive degeneration seen in LCA/EOSRD.
Congenital stationary night blindness Can be differentiated on the basis of ERG phenotype and natural history.94
Ocular and oculocutaneous albinism Clinical examination (skin, hair, eyebrows/eyelashes; iris and retina), retinal imaging (OCT and FAF) and electrophysiological 
assessment.
Optic nerve hypoplasia Clinical examination and electrophysiological assessment. Of note, absent pupil reflexes suggests severe optic nerve hypoplasia 
rather than LCA.
Batten disease Infantile Neuronal Ceroid Lipofuscinosis (NCL) presents with congenital or early- onset blindness, with onset by age 6 months; 
whereas patients with Late and Juvenile onset NCL present at 2–4 and 6 years of age or older, respectively. Patients with NCL have 
neurocognitive decline and can have epilepsy.
Joubert syndrome Patients present with severe visual impairment, ocular motor abnormalities, often have the ‘molar tooth’ sign on MRI and develop 
nephronophthisis in later childhood.
Peroxisomal diseases Associated features include sensorineural deafness, dysmorphic features, developmental delay, hepatomegaly and early death.
Alstrom syndrome Presents with infantile onset nystagmus, photophobia and a cone–rod dystrophy on electrophysiological assessment. Other systemic 
features include childhood obesity, hyperinsulinaemia, type 2 diabetes mellitus, hepatic dysfunction, heart failure, sensorineural 
hearing loss and renal failure.
Cobalamin C deficiency Has a variable phenotype with severely affected individuals showing progressive, infantile onset, metabolic, neurological and 
ophthalmic manifestations, including infantile nystagmus, bulls-eye maculopathy and reduced responses on ERG.
EOSRD, early-onset severe retinal dystrophy; FAF, fundus autofluorescence; LCA, Leber congenital amaurosis; OCT, optical coherence tomography.
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They reported improvements and normalisation in the visual 
pathway corresponding to the retinal injection areas in the 
treated eyes, which were maintained over time, compared with 
the visual pathway for the untreated eyes which continued to 
deteriorate. This would support the belief that early intervention 
would be most likely to result in the greatest benefit. However, 
of note the 10 subjects in this study were aged 9 to 45 years, 
suggesting that intervention in adulthood could still be benefi-
cial.
Furthermore, recently, one phase III trial (NCT00999609) 
and a phase I/II trial (NCT01496040) have been completed 
with another two  phase I/II trials ( clinicaltrials. gov identifiers: 
NCT02781480, NCT00821340,) now underway.
Pharmacological intervention has also been investigated 
to potentially overcome the biochemical blockade, following 
successful rescue in animal models.54 55 A phase I/II clinical trial 
examining the efficacy of the synthetic prodrug QLT091001, a 
precursor to 9-cis-retinal, has been conducted in 18 patients (13 
with RPE65-LCA and five with LRAT-LCA—as both encoded 
proteins participate in the retinoid cycle (figure 1)).56 Patients 
received a once-daily oral dose of 40 mg/m2/day for 7 consecu-
tive days. Following this, 44% of patients had a >20% increase 
in isopter area in one or both eyes, as assessed by Goldmann 
visual  field  testing,  and  67%  of  patients  showed  a>5 ETDRS 
letter score increase in one or both eyes.56 A phase III trial is due 
to commence in the near future.
AIPL1-associated LCA
AIPL1 encodes Aryl-hydrocarbon-interacting-protein-like 1—a 
photoreceptor-specific cochaperone that interacts specifically 
with the molecular chaperone HSP90 to modulate the stability 
of and assembly of the HSP90 substrate, retinal cGMP phospho-
diesterase.57 58
Sequence variants in AIPL1 are associated with a relatively 
severe congenital LCA phenotype, with severe and rapidly 
progressive visual loss, accounting for less than 5% of LCA.9 59 60 
Aboshiha et al investigated a worldwide cohort of 42 molec-
ularly confirmed patients, collecting data on demographics, 
visual acuity, fundus examination, OCT findings and geno-
type. This  study  identified p.W278X (c.834G>A) as  the most 
common AIPL1 variant, occurring in at least one allele in 62% of 
patients.61 Interestingly, hand-held OCT imaging identified four 
patients (three of whom harboured the aforementioned common 
variant) with relative preservation of central outer retinal struc-
ture, all of whom were younger than 4 years of age.61
Gene replacement therapy using an AAV2/8 vector in an AIPL1 
knock-out mouse model has been shown to result in restoration 
of cellular function with photoreceptor cell preservation and 
improved retinal function, despite the severe rapidly progressive 
early-onset retinal degeneration seen in this mouse model.62 The 
early visual loss to perception of light or worse, the high-resolu-
tion OCT evidence of retained outer retinal structure early in life 
and the successfully treated animal models, raise the possibility 
of a gene therapy-based approach in AIPL1-LCA early in life; 
with a human clinical interventional study being in the advanced 
stages of development.
RPGRIP1-associated LCA
RPGRIP1-LCA is believed to be responsible for approxi-
mately 5% of cases.63 64 RPGRIP1 is a binding partner of reti-
nitis pigmentosa GTPase regulator (RPGR) and is essential for 
anchoring RPGR at the connecting cilia between the inner and 
outer segments of photoreceptor cells.65–69
In contrast to other forms of LCA, RPGRIP1-LCA appears 
to be relatively non-progressive, following an initial rapid 
decline in visual function.18 Furthermore, photoreceptors in 
the central retina appear to remain present for a significant 
period following deterioration of visual function.70 These 
features suggest a wide window of opportunity for potential 
intervention.
An RPGRIP1 knock-out mouse and RPGRIP1 deficient 
mouse and dog models have been characterised and have 
provided models for preclinical gene replacement studies.55–57 
In RPGRIP1 knock-out mice, both improved outer segment 
morphology and photoreceptor survival, and better pres-
ervation of ERG responses have been demonstrated with 
RPGRIP1 gene replacement using both AAV2 and AAV8 
vectors.71 72 Improved photoreceptor function up to 24 months 
postsubretinal injection has also been shown in the canine 
model.73
CRB1-associated LCA
Disease-causing sequence variants in CRB1 have been iden-
tified in a broad range of phenotypes, including the early-
onset disorders LCA/EOSRD and retinitis pigmentosa with 
and without a Coats-like vasculopathy, a later-onset macular 
dystrophy and isolated autosomal recessive foveal reti-
noschisis.74–77  Approximately  10%  of  LCA/EOSRD  patients 
harbour variants in CRB1.9 18 The CRB1 protein is known to 
colocalise with the zonula adherens, forming a major compo-
nent of the outer limiting membrane and is believed to have a 
role in retinal development.
Both the severity and rate of progression vary significantly 
between patients with CRB1-associated LCA/EOSRD, with 
clinical examination and OCT findings often allowing directed 
molecular screening of CRB1.74 75 78 Characteristic findings 
include macular atrophy, nummular pigmentation, relative 
para-arteriolar preservation of the RPE and retinal thickening 
with loss of lamination—in direct contrast to other forms of 
LCA/EOSRD where progressive retinal thinning is common-
place.
CEP290-associated LCA
CEP290-LCA/EOSRD accounts for 15%–20% of cases, thereby 
representing one of the most common genetic causes.17 CEP290 
localises to the centromeres and the connecting cilia of photo-
receptors. The intronic variant c.2991+1655 A>G is the most 
common disease-causing mutation (especially in European coun-
tries and in the USA), having been identified in at least one allele 
in 77% of patients (n=43) in a study of CEP290-LCA.79
Retinal examination can be relatively normal in infancy 
with significant variability in visual function, with no correla-
tion between age and visual acuity (VA) noted over an average 
follow-up period of 10 years; although severe VA loss (counting 
fingers or worse) is seen in most, but not all, children in the first 
decade.17 79 80
Interestingly, OCT studies have shown that despite 
profound cone dysfunction, the foveal outer nuclear layer 
(cone nuclei) is structurally detectable until the fourth decade 
of life in some patients, although with abnormal inner and 
outer segments in contrast to the early loss of rod photo-
receptors.81 These findings suggest a potential window of 
opportunity—wider for possible cone rescue than rod. Gene 
therapy-based intervention has been explored in vitro with a 
lentiviral vector containing human CEP290 and been shown 
to effectively transduce patient-specific induced pluripotent 
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stem cell-derived photoreceptor precursor cells and rescue the 
cellular phenotype.82 Other molecular therapeutic avenues 
being explored focus on the common deep intronic CEP290 
sequence variant, which creates a strong splice donor site that 
leads to the insertion of a cryptic exon encoding a prema-
ture stop codon. Several approaches have been suggested, 
including the use of antisense oligonucleotide-mediated exon 
skipping to abrogate the disease-causing variant or correc-
tion of the splice defect using CRISPR/Cas9-mediated gene 
editing.83 84 Both of these novel approaches show promise 
and human clinical trials are anticipated in the near future.85
RDH12-associated LCA
Disease-causing sequence variants in RDH12 are identified in 
up  to approximately 10% of LCA/EOSRD patients.9 19RDH12 
encodes retinol dehydrogenase 12, a component of the visual 
cycle, which when deficient is believed to result in retinal toxicity 
secondary to all-trans-retinal accumulation.86
Most patients with biallelic RDH12 mutations have an 
EOSRD rather than LCA phenotype. There is a recognisable 
fundus phenotype with widespread RPE and retinal atrophy 
and minimal intraretinal pigmentation in early childhood, with 
dense intraretinal bone-spicule pigmentation developing over 
time (figure 2).19 There is early progressive macular atrophy, 
with pigmentation and yellowing and corresponding macular 
excavation on OCT and loss of fundus autofluorescence.19
Promising results of AAV2/8-vector-mediated RDH12 gene 
replacement therapy in Rdh12 knock-out mice has raised the 
possibility of human clinical trials in the future.87
LRAT-associated LCA
LRAT encodes Lecithin:retinol acyl transferase, a key enzyme in 
the vitamin A recycling pathway (visual cycle), with LRAT defi-
ciency associated with a similar phenotype to RPE65-deficiency, 
although being far less common.9 88 As described for RPE65-de-
ficiency, the synthetic prodrug QLT091001, a precursor to 
9-cis-retinal, has been shown in a phase I trial to improve VA and 
kinetic visual fields in LRAT-LCA, with a phase III trial antici-
pated in the future.
therapeutic advances potentially applicable to advanced LcA
Stem cell therapies hold great promise for the future to restore 
lost retinal cells in advanced disorders, including potentially 
LCA. At present, human stem cell therapy has primarily been 
confined to RPE transplantation, with two phase I/II studies 
reporting safe transplantation of human embryonic stem cell-de-
rived RPE and induced pluripotent stem cell-derived RPE, 
respectively.89 90 However, transplantation of other retinal cells, 
including photoreceptors—which would be needed in LCA, 
remains at a preclinical stage.
Clinical trials have also been conducted to investigate the 
therapeutic potential of electronic retinal prostheses in advanced 
retinal degeneration including choroideremia and retinitis 
pigmentosa. At present, current epiretinal or subretinal devices 
cannot sufficiently replace the high density of photoreceptors 
at the fovea and have thereby resulted in very low levels of VA 
improvement in a minority of patients, with a varied safety 
profile.91–93
concLusIons
Improvements in molecular genetic testing and clinical assess-
ments (primarily quantitative high-resolution retinal imaging) 
have led to a greater understanding of genotype–phenotype 
correlations and structure–function associations in LCA/
EOSRD. This coupled with advances in gene therapy in both 
animal model studies and human clinical trials have resulted 
in a current new era of increasing clinical trials for multiple 
genetic subtypes of LCA/EOSRD and the cautious optimism for 
the development of proven successful and durable treatments 
which both improve visual function and halt/markedly slow 
retinal degeneration. Substantial challenges remain however, 
particularly for patients with severe visual loss from birth where 
normal visual pathway function has never been established, 
with intervention likely needed very early in infancy to fully 
address any potential cortical limitations and thereby optimise 
outcomes.
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